Detection of Borrelia burgdorferi nucleic acids after antibiotic treatment does not confirm viability

Journal of Clinical Microbiology

Volumn 51, Issue 3, 2013, Pages 857-862

  Iyer, Radha ^a   Mukherjee, Priyanka ^a   Wang, Kemeng ^a   Simons, Joshua ^a   Wormser, Gary P ^a   Schwartz, Ira ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 PHOSPHOFRUCTOKINASE; ANTIBIOTIC AGENT; BACTERIAL DNA; CEFTRIAXONE; MESSENGER RNA; OUTER SURFACE PROTEIN A;

ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL GENE; BACTERIAL GROWTH; BACTERIAL METABOLISM; BACTERIAL SURVIVAL; BACTERIAL VIABILITY; BACTERIUM CULTURE; BACTERIUM ISOLATE; BARBOUR STOENNER KELLY MEDIUM; BORRELIA BURGDORFERI; CONTROLLED STUDY; CULTURE MEDIUM; DNA DETERMINATION; FLAB GENE; MICROBIAL MORPHOLOGY; NONHUMAN; OSPA GENE; OSPC GENE; PFK GENE; PH; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ANALYSIS;

ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIOLOGICAL TECHNIQUES; BORRELIA BURGDORFERI; CEFTRIAXONE; DNA, BACTERIAL; HUMANS; LYME DISEASE; MICROBIAL VIABILITY; POLYMERASE CHAIN REACTION; TIME FACTORS;

EID: 84874074445     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.02785-12     Document Type: Article

References (41)

1. Centers for Disease Control and Prevention. 2012. Final 2011 reports of nationally notifiable diseases.MMWRMorb. Mortal. Wkly. Rep. 61:624-627
2. Wormser GP, Dattwyler RJ, Shapiro ED, Halperin JJ, Steere AC, Klempner MS, Krause PJ, Bakken JS, Strle F, Stanek G, Bockenstedt L, Fish D, Dumler JS, Nadelman RB. 2006. The clinical assessment, treatment, and prevention of Lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America. Clin. Infect. Dis. 43:1089-1134
3. Cerar D, Cerar T, Ruzic-Sabljic E, Wormser GP, Strle F. 2010. Subjective symptoms after treatment of early Lyme disease. Am. J. Med. 123:79-86
4. Nowakowski J, Nadelman RB, Sell R, McKenna D, Cavaliere LF, Holmgren D, Gaidici A, Wormser GP. 2003. Long-term follow-up of patients with culture-confirmed Lyme disease. Am. J. Med. 115:91-96
5. Fallon BA, Keilp JG, Corbera KM, Petkova E, Britton CB, Dwyer E, Slavov I, Cheng J, Dobkin J, Nelson DR, Sackeim HA. 2008. A randomized, placebo-controlled trial of repeated IV antibiotic therapy for Lyme encephalopathy. Neurology 70:992-1003
6. Klempner MS, Hu LT, Evans J, Schmid CH, Johnson GM, Trevino RP, Norton D, Levy L, Wall D, McCall J, Kosinski M, Weinstein A. 2001. Two controlled trials of antibiotic treatment in patients with persistent symptoms and a history of Lyme disease. N. Engl. J. Med. 345:85-92
7. Krupp LB, Hyman LG, Grimson R, Coyle PK, Melville P, Ahnn S, Dattwyler R, Chandler B. 2003. Study and treatment of post Lyme disease (STOP-LD): a randomized double masked clinical trial. Neurology 60: 1923-1930
8. Li X, McHugh GA, Damle N, Sikand VK, Glickstein L, Steere AC. 2011. Burden and viability of Borrelia burgdorferi in skin and joints of patients with erythema migrans or lyme arthritis. Arthritis Rheum. 63:2238-2247
9. Wormser GP, Nadelman RB, Schwartz I. 2012. The amber theory of Lyme arthritis: initial description and clinical implications. Clin. Rheumatol. 31:989-994
10. Bockenstedt LK, Gonzalez DG, Haberman AM, Belperron AA. 2012. Spirochete antigens persist near cartilage after murine Lyme borreliosis therapy. J. Clin. Invest. 122:2652-2660
11. Embers ME, Barthold SW, Borda JT, Bowers L, Doyle L, Hodzic E, Jacobs MB, Hasenkampf NR, Martin DS, Narasimhan S, Phillippi-Falkenstein KM, Purcell JE, Ratterree MS, Philipp MT. 2012. Persistence of Borrelia burgdorferi in rhesus macaques following antibiotic treatment of disseminated infection. PLoS ONE 7:e29914. doi:10.1371/journal .pone.0029914
12. Wormser GP, Schwartz I. 2009. Antibiotic treatment of animals infected with Borrelia burgdorferi. Clin. Microbiol. Rev. 22:387-395
13. Wormser GP, Baker PJ, O'Connell S, Pachner AR, Schwartz I, Shapiro ED. 2012. Critical analysis of treatment trials of rhesus macaques infected with Borrelia burgdorferi reveals important flaws in experimental design. Vector Borne Zoonotic Dis. 12:535-538
14. Barthold SW, Hodzic E, Imai DM, Feng S, Yang X, Luft BJ. 2010. Ineffectiveness of tigecycline against persistent Borrelia burgdorferi. Antimicrob. Agents Chemother. 54:643-651
15. Lewis K. 2007. Persister cells, dormancy and infectious disease. Nat. Rev. Microbiol. 5:48-56
16. Lewis K. 2010. Persister cells. Annu. Rev. Microbiol. 64:357-372
17. Elias AF, Stewart PE, Grimm D, Caimano MJ, Eggers CH, Tilly K, Bono JL, Akins DR, Radolf JD, Schwan TG, Rosa P. 2002. Clonal polymorphism of Borrelia burgdorferi strain B31 MI: implications for mutagenesis in an infectious strain background. Infect. Immun. 70:2139-2150
18. Wang G, Ojaimi C, Iyer R, Saksenberg V, McClain SA, Wormser GP, Schwartz I. 2001. Impact of genotypic variation of Borrelia burgdorferi sensu stricto on kinetics of dissemination and severity of disease in C3H/ HeJ mice. Infect. Immun. 69:4303-4312
19. Schwartz I, Wormser GP, Schwartz JJ, Cooper D, Weissensee P, Gazumyan A, Zimmermann E, Goldberg NS, Bittker S, Campbell GL, Pavia CS. 1992. Diagnosis of early Lyme disease by polymerase chain reaction amplification and culture of skin biopsies from erythema migrans lesions. J. Clin. Microbiol. 30:3082-3088
20. Liveris D, Schwartz I, Bittker S, Cooper D, Iyer R, Cox ME, Wormser GP. 2011. Improving the yield of blood cultures from patients with early Lyme disease. J. Clin. Microbiol. 49:2166-2168
21. Malawista SE, Barthold SW, Persing DH. 1994. Fate of Borrelia burgdorferi DNA in tissues of infected mice after antibiotic treatment. J. Infect. Dis. 170:1312-1316
22. Straubinger RK, Summers BA, Chang YF, Appel MJ. 1997. Persistence of Borrelia burgdorferi in experimentally infected dogs after antibiotic treatment. J. Clin. Microbiol. 35:111-116
23. Takayama K, Kjelleberg S. 2000. The role of RNA stability during bacterial stress responses and starvation. Environ. Microbiol. 2:355-365
24. Donovan WP, Kushner SR. 1986. Polynucleotide phosphorylase and ribonuclease II are required for cell viability and mRNA turnover in Escherichia coli K-12. Proc. Natl. Acad. Sci. U. S. A. 83:120-124
25. Keer JT, Birch L. 2003. Molecular methods for the assessment of bacterial viability. J. Microbiol. Methods 53:175-183
26. Sheridan GE, Masters CI, Shallcross JA, Mackey BM. 1998. Detection of mRNA by reverse transcription-PCR as an indicator of viability in Escherichia coli cells. Appl. Environ. Microbiol. 64:1313-1318
27. Dawson CC, Intapa C, Jabra-Rizk MA. 2011. "Persisters": survival at the cellular level. PLoS Pathog. 7:e1002121. doi:10.1371/journal. ppat .1002121
28. Bockenstedt LK, Mao J, Hodzic E, Barthold SW, Fish D. 2002. Detection of attenuated, noninfectious spirochetes in Borrelia burgdorferi-infected mice after antibiotic treatment. J. Infect. Dis. 186:1430-1437
29. Brorson O, Brorson SH, Scythes J, MacAllister J, Wier A, Margulis L. 2009. Destruction of spirochete Borrelia burgdorferi round-body propagules (RBs) by the antibiotic tigecycline. Proc. Natl. Acad. Sci. U. S. A. 106:18656-18661
30. Baradaran-Dilmaghani R, Stanek G. 1996. In vitro susceptibility of thirty Borrelia strains from various sources against eight antimicrobial chemotherapeutics. Infection 24:60-63
31. Ates L, Hanssen-Hubner C, Norris DE, Richter D, Kraiczy P, Hunfeld KP. 2010. Comparison of in vitro activities of tigecycline, doxycycline, and tetracycline against the spirochete Borrelia burgdorferi. Ticks Tick Borne Dis. 1:30-34
32. Pavia C, Inchiosa MA, Jr, Wormser GP. 2002. Efficacy of short-course ceftriaxone therapy for Borrelia burgdorferi infection in C3H mice. Antimicrob. Agents Chemother. 46:132-134
33. Cenciarini-Borde C, Courtois S, La Scola B. 2009. Nucleic acids as viability markers for bacteria detection using molecular tools. Future Microbiol. 4:45-64
34. Sheridan GE, Szabo EA, Mackey BM. 1999. Effect of post-treatment holding conditions on detection of tufA mRNA in ethanol-treated Escherichia coli: implications for RT-PCR-based indirect viability tests. Lett. Appl. Microbiol. 29:375-379
35. Birch L, Dawson CE, Cornett JH, Keer JT. 2001. A comparison of nucleic acid amplification techniques for the assessment of bacterial viability. Lett. Appl. Microbiol. 33:296-301
36. Reimann S, Grattepanche F, Rezzonico E, Lacroix C. 2010. Development of a real-time RT-PCR method for enumeration of viable Bifidobacterium longum cells in different morphologies. Food Microbiol. 27:236-242
37. Sung KD, Stern NJ, Hiett KL. 2004. Relationship of messenger RNA reverse transcriptase-polymerase chain reaction signal to Campylobacter spp. viability. Avian Dis. 48:254-262
38. Moody KD, Adams RL, Barthold SW. 1994. Effectiveness of antimicrobial treatment against Borrelia burgdorferi infection in mice. Antimicrob. Agents Chemother. 38:1567-1572
39. Kazragis RJ, Dever LL, Jorgensen JH, Barbour AG. 1996. In vivo activities of ceftriaxone and vancomycin against Borrelia spp. in the mouse brain and other sites. Antimicrob. Agents Chemother. 40:2632-2636
40. Straubinger RK. 2000. PCR-based quantification of Borrelia burgdorferi organisms in canine tissues over a 500-day postinfection period. J. Clin. Microbiol. 38:2191-2199
41. Hodzic E, Feng S, Holden K, Freet KJ, Barthold SW. 2008. Persistence of Borrelia burgdorferi following antibiotic treatment in mice. Antimicrob. Agents Chemother. 52:1728-1736.